Pathogenesis, clinical manifestations and treatment approaches for diabetic polyneuropathy
https://doi.org/10.21518/2079-701X-2013-12-43-49
Abstract
The article details the pathogenesis of diabetic polyneuropathy (DPN) and tells about the stages and types of DPN presentation. The importance of timely differential diagnosis of neuropathic and ischemic forms of diabetic foot is emphasized. Particular attention is paid to the role of alpha-lipoic acid in the pathogenetic therapy of diabetic polyneuropathy.
References
1. International Guidelines on Outpatient management of Diabetic Peripheral Neuropathy, 1995, 17P
2. Feldman EL, Stevens MJ et al. 2002.Somatosensory neuropathy. In Elltnberg and Rifkin's diabetes mellitus. D. Porte, R.S. Sherwin and A. Baron, editors. McGraw Hill. New York, USA. 772-788.
3. Vinik AI et al. 2002. Diabetic autonomic neuropathy. In Elltnberg and Rifkin's diabetes mellitus. D. Porte, R.S. Sherwin and A. Baron, editors. McGraw Hill. New York, USA. 789-804.
4. Dyck PJ, Karnes JL, O'Brien PC. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity Neurology,1992;42:1164-1170.
5. Dyck PJ, Litchy WJ, Lehman NA et al. Variables influences neuropathic endpoints. The Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology, 1995;45:1115-1121.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of Diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993;70:1009-1018.
7. Russel JW, Sullivan KA, Windebank AJ, Hermann DN, Feldmann EL. Neurons undergo apoptosis in animal andmcell culture models of diabetes. Neurobiol. Dis., 1999;6:347-363.
8. Russel JW et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB, 2002;16:1738-1748.
9. Schmeichel AM, Schmelzer JD, and Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy Diabetes, 2003;52:165-171.
10. Stevens MJ, Obrosova I, Pop-Busui R, Greene DA, and Feldman EL. Patogenesis of diabetic neuropathy. 2002. In Elltnberg and Rifkin's diabetes mellitus. D. Porte, R.S. Sherwin and A. Baron, editors. McGraw Hill. New York, USA. 747-770.
11. Apfel SC. Neurotrophic factors in diabetic peripheral neuropathy. Eur. Neurol, 1999;41 (Suppl. 1):27-34.
12. Tomlinson DR, Fernyhough P, and Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes, 1999;46:S43-S49.
13. Feldman TL and Windebank AJ. Growth factors and peripheral neuropathy. 1998. In Diabetic neuropathy. PJ. Dyck and P.K. Tomas, editors. W.B. Saunders Co. Phil. USA, 377-386.
14. Комелягина Е.Ю. Алгоритм выявления пациентов из группы риска развития синдрома диабетической стопы. Дисс. на соиск. уч. степ. канд. мед. наук. М., 1998.
15. Ziegler D, Reljanovic M, Mehnert H, Gries FA. a-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. End. Diabetes. 1999;107:421-430.
16. Корпачев В.В. Щербак А. Тиоктовая кислота: проблемы и перспективы использования. Екник фармакологи та фармацп, 2003;3:20-28.
17. Корпачев В.В., Борщевская М.И. Лекарственные формы тиоктовой кислоты. Проблеми ендокринног патологи, 2006;1:74-86.
18. Clayton GD. et al. «Polyethylene glycols» in Patty's Industrial hygiene and toxicology. 4th еd.; Eds.; John Wiley & Sons. Inc.: New York, 1994;II(F):4666-4671.
19. Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Sch tte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D. vEffects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med, 1999;16:1040-1043.
20. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. Diabetes Care, 2003;26:770-776.
21. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes care, 2006;29:2365-2370.
22. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care, 1997;20:369-73.
23. Ziegler D et al. Abstracts of the 43rd European Association for the Study of Diabetes (EASD) annual meeting, 18-21 September 2007, Amsterdam, The Netherlands. Diabetologia, 2007;50 (Suppl. 1)S0138).
24. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev, 2011;7:208-20.
25. Корпачев В.В. Щербак А. Тиоктовая кислота: проблемы и перспективы использования. Екник фармакологи та фармацп, 2003;3:20-28.
26. Clayton GD et al. «Polyethylene glycols» in Patty's Industrial hygiene and toxicology 4th еd.; Eds.; John Wiley & Sons. Inc.: New York, 1994;II(F):4666-4671.
27. Корпачев В.В., Борщевская М.И. Лекарственные формы тиоктовой кислоты. Проблеми ендокринног патологи, 2006;1:74-86.
Review
For citations:
Nedosugova LV. Pathogenesis, clinical manifestations and treatment approaches for diabetic polyneuropathy. Meditsinskiy sovet = Medical Council. 2013;(12):43-49. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-43-49
Views:
379
Email this article 